Immunocore Holdings plc will report second quarter financial results on August 7, 2025, before the US markets open. A live teleconference and webcast will follow at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide an update on their business and portfolio. The call will be webcast live on the company’s website, with a replay available afterward. Immunocore is a biotechnology company developing TCR bispecific immunotherapies to treat cancer, autoimmune diseases, and infectious diseases. Its most advanced oncology therapeutic, KIMMTRAK, has been approved for the treatment of adult patients with uveal melanoma.

Read more at GlobeNewswire: Immunocore to report second quarter 2025 financial results